Prevention of Skin Cancer in Xeroderma Pigmentosum with the Use of Oral Isotretinoin
- 23 June 1988
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 318 (25), 1633-1637
- https://doi.org/10.1056/nejm198806233182501
Abstract
To confirm reports that skin cancer can be prevented with retinoids, we conducted a three-year controlled prospective study of oral isotretinoin (also called 13-cis retinoic acid) in five patients with xeroderma pigmentosum who had a history of multiple cutaneous basal-cell or squamous-cell carcinomas. Patients were treated with isotretinoin at a dosage of 2 mg per kilogram of body weight per day for two years and then followed for an additional year, without the drug. Before, during, and after treatment, biopsies of all suspicious lesions were performed, and skin cancers were surgically removed.Keywords
This publication has 13 references indexed in Scilit:
- EFFECT OF 13-cis-RETINOIC ACID ON SURVIVAL OF PATIENTS WITH MYELODYSPLASTIC SYNDROMEThe Lancet, 1987
- Xeroderma PigmentosumArchives of Dermatology, 1987
- Long-Term Retinoid Therapy Is Needed for Maintenance of Cancer Chemopreventive EffectDermatology, 1987
- 13-cis-Retinoic Acid in the Treatment of Oral LeukoplakiaNew England Journal of Medicine, 1986
- Cutaneous chemical carcinogenesisJournal of the American Academy of Dermatology, 1986
- Xeroderma pigmentosumClinics in Dermatology, 1985
- Aromatic Retinoid in the Chemoprevention of the Progression of Nevoid Basal‐Cell Carcinoma SyndromeThe Journal of Dermatologic Surgery and Oncology, 1984
- DNA repair protects against cutaneous and internal neoplasia: evidence from xeroderma pigmentosumCarcinogenesis: Integrative Cancer Research, 1984
- Chemoprevention of basal cell carcinoma with isotretinoinJournal of the American Academy of Dermatology, 1982
- Treatment of Darier’s Disease, Lamellar Ichthyosis, Pityriasis Rubra Pilaris, Cystic Acne, and Basal Cell Carcinoma with Oral 13-cis-Retinoic AcidDermatology, 1978